Evidence map›Paper›PMID 42249812›Full record

ArticleACS chemical neuroscience2026

Discovery of VU6053371/BI03738809: A First-in-Class Selective and CNS-Penetrant mGlu

Caleb A Jones, Renn A Duncan, Kristen M Gilliland, Carson W Reed, Daniel H Haymer, Paul K Spearing, Rory A Capstick, Bartholomew P Roland, Paige Vinson, Marc Quitalig and 19 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS chemical neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Discovery of VU6052959/BI'7927: A Selective mGluACS medicinal chemistry letters · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Caleb A JonesWarren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States.ORCID 0000-0002-0471-9392
Renn A DuncanWarren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States.
Kristen M GillilandWarren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States.
Carson W ReedWarren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States.
Daniel H HaymerWarren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States.
Paul K SpearingWarren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States.
Rory A CapstickWarren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States.
Bartholomew P RolandWarren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States.ORCID 0000-0002-9033-9942
Paige VinsonWarren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States.
Marc QuitaligWarren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States.
Caroline BaggeroerWarren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States.
Natasha B BillardWarren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States.
Jonathan W DickersonWarren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States.
Zixiu XiangWarren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States.ORCID 0000-0002-1678-209X
Valerie M KramlingerWarren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States.
Olivier BoutaudWarren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States.
Julia SchlichtigerBoehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach, Germany.
Carrie K JonesWarren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States.
Colleen M NiswenderWarren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States.ORCID 0000-0001-6009-8212
Hyekyung P ChoWarren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States.
Jerri L RookWarren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States.
Carsten T WotjakBoehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach, Germany.
Matthias FreiwaldBoehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach, Germany.
Riccardo GiovanniniBoehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach, Germany.
Heiko SommerBoehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach, Germany.
Scott HobsonBoehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach, Germany.
P Jeffrey ConnWarren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States.
Bruce J MelanconWarren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States.ORCID 0000-0002-1958-0071
Craig W LindsleyWarren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States.ORCID 0000-0003-0168-1445

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Herein, we report the discovery and development of the first-in-class (FIC), selective, and centrally active metabotropic glutamate receptor subtype 3 (mGlu

Indexed as

CognitionReceptors, Metabotropic GlutamateThiophenesAllosteric RegulationAnimalsBrainCognitive EnhancementHumansMaleRatsRats, Sprague-DawleyRecognition, Psychologymetabotropic glutamate receptor 3Receptors, Metabotropic GlutamateThiophenescognitionmetabolismmetabotropic glutamate receptor subtype 3 (mGlu3)novel object recognitionpharmacokineticspositive allosteric modulator (PAM)

Identifiers

PMID42249812
PMCPMC13281392

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.